source
- Bristol Myers Squibb emphasizes pipeline strength and later-stage partnership focus amid patent cliff concernsBristol Myers Squibb used its latest earnings call to outline how it plans to address an upcoming patent cliff that threatens revenue from several key products. Executives said the company is rely…
- BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapyBioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…